Last reviewed · How we verify
IMRECOXIB
At a glance
| Generic name | IMRECOXIB |
|---|---|
| Sponsor | HengRui |
| Target | Prostaglandin G/H synthase 2 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Osteoarthritis
Common side effects
Key clinical trials
- A Randomized Open-labeled Study for Comparing Methods of Using Imrecoxib to Treat AS (NA)
- A Multicenter，Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis (PHASE4)
- Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency (PHASE1)
- A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers (PHASE1)
- A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMRECOXIB CI brief — competitive landscape report
- IMRECOXIB updates RSS · CI watch RSS
- HengRui portfolio CI